Stay Up to Date
with SHINE

Explore how n.c.a. lutetium-177-based therapy precisely targets and treats cancer using radioactive properties. Learn about its unique ability to destroy cancer cells while minimizing damage to healthy tissue.

Pre-clinical research results show that WARF Therapeutics’ WT-7695 radiopharmaceutical, which uses SHINE’s Ilumira, achieved 100% survival in a model of kidney cancer. ART-101, a novel prostate cancer treatment developed at the Advanced Radiotheranostics Lab using SHINE’s Ilumira, demonstrates superior efficacy compared to current therapies

University Medical Center Groningen’s collaboration with SHINE aims to advance cancer research and secure the medical supply chain of critical isotopes in Europe

The two organizations join forces to improve global access to radiopharmaceutical therapy, with the Oncidium foundation aiming to provide 2,000 doses in five years through the initiative

SHINE receives a second grant from the Department of Energy’s Small Business Innovation Research project, supporting its Phase 3 efforts to recycle nuclear waste. The company hires industry leader Todd Caccamo as CRO to drive commercial expansion

Glytherix Ltd announced today a new global clinical supply agreement with SHINE Technologies for non-carrier added lutetium-177 (n.c.a. Lu-177)

Our team joined hundreds of community members at the Town Square Pavilion for the 31st annual walk. This year, thanks to the incredible generosity of our employees and vendors, we raised over $8,600 for the American Heart Association

Transformational leaders join SHINE to guide the company through next stages of growth and profitability

TOFE 2024 spotlights fusion's future: collaboration is key, near-term value creation crucial. Industry leaders, including SHINE, discuss workforce challenges and simplifying fusion tech. Dive into insights shaping our industry's path forward.

FLARE enables faster, more comprehensive radiation effects testing to better protect national security, including mission critical components and infrastructure

To fund its vision of generating power from fusion, SHINE Technologies aims first to revolutionize medical isotope production

The award will support progress on Chrysalis, SHINE’s large-scale medical isotope production facility in Janesville, Wisconsin

Cincinnati Children’s Hospital needed Lu-177 for scanner calibration, a crucial step in ensuring the safe and effective delivery of targeted radiotherapy to young patients. It was Sunday, and the dose was needed in-hand by Thursday to keep a patient’s treatment schedule on course

SHINE and Zeno enter an MOU to develop radioisotope supply chain for power systems that enable persistent operations from the seabed to the lunar surface

Blue Earth Therapeutics will leverage SHINE’s non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials